It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ANIP’s FA Score shows that 1 FA rating(s) are green whileORGO’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ANIP’s TA Score shows that 5 TA indicator(s) are bullish while ORGO’s TA Score has 4 bullish TA indicator(s).
ANIP (@Pharmaceuticals: Generic) experienced а +7.35% price change this week, while ORGO (@Pharmaceuticals: Generic) price change was +3.84% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +4.25%. For the same industry, the average monthly price growth was +10.98%, and the average quarterly price growth was +78.05%.
ANIP is expected to report earnings on Nov 05, 2025.
ORGO is expected to report earnings on Nov 05, 2025.
A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
ANIP | ORGO | ANIP / ORGO | |
Capitalization | 1.9B | 600M | 316% |
EBITDA | 66.9M | -274K | -24,416% |
Gain YTD | 58.231 | 47.812 | 122% |
P/E Ratio | 51.82 | 63.75 | 81% |
Revenue | 674M | 459M | 147% |
Total Cash | 155M | 110M | 141% |
Total Debt | 623M | 42.6M | 1,462% |
ANIP | ORGO | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 25 | 80 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 93 Overvalued | 77 Overvalued | |
PROFIT vs RISK RATING 1..100 | 26 | 95 | |
SMR RATING 1..100 | 91 | 92 | |
PRICE GROWTH RATING 1..100 | 37 | 38 | |
P/E GROWTH RATING 1..100 | 93 | 11 | |
SEASONALITY SCORE 1..100 | 15 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ORGO's Valuation (77) in the Financial Conglomerates industry is in the same range as ANIP (93) in the Pharmaceuticals Other industry. This means that ORGO’s stock grew similarly to ANIP’s over the last 12 months.
ANIP's Profit vs Risk Rating (26) in the Pharmaceuticals Other industry is significantly better than the same rating for ORGO (95) in the Financial Conglomerates industry. This means that ANIP’s stock grew significantly faster than ORGO’s over the last 12 months.
ANIP's SMR Rating (91) in the Pharmaceuticals Other industry is in the same range as ORGO (92) in the Financial Conglomerates industry. This means that ANIP’s stock grew similarly to ORGO’s over the last 12 months.
ANIP's Price Growth Rating (37) in the Pharmaceuticals Other industry is in the same range as ORGO (38) in the Financial Conglomerates industry. This means that ANIP’s stock grew similarly to ORGO’s over the last 12 months.
ORGO's P/E Growth Rating (11) in the Financial Conglomerates industry is significantly better than the same rating for ANIP (93) in the Pharmaceuticals Other industry. This means that ORGO’s stock grew significantly faster than ANIP’s over the last 12 months.
ANIP | ORGO | |
---|---|---|
RSI ODDS (%) | 1 day ago72% | 1 day ago85% |
Stochastic ODDS (%) | 1 day ago74% | 1 day ago85% |
Momentum ODDS (%) | 1 day ago75% | 1 day ago75% |
MACD ODDS (%) | 1 day ago70% | 1 day ago84% |
TrendWeek ODDS (%) | 1 day ago75% | 1 day ago81% |
TrendMonth ODDS (%) | 1 day ago75% | 1 day ago80% |
Advances ODDS (%) | 3 days ago74% | 4 days ago79% |
Declines ODDS (%) | 17 days ago69% | 11 days ago87% |
BollingerBands ODDS (%) | 1 day ago75% | 1 day ago90% |
Aroon ODDS (%) | 1 day ago72% | 1 day ago89% |
A.I.dvisor indicates that over the last year, ANIP has been loosely correlated with ORGO. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ANIP jumps, then ORGO could also see price increases.
Ticker / NAME | Correlation To ANIP | 1D Price Change % | ||
---|---|---|---|---|
ANIP | 100% | -2.81% | ||
ORGO - ANIP | 45% Loosely correlated | +0.64% | ||
DRRX - ANIP | 38% Loosely correlated | +0.53% | ||
ESPR - ANIP | 31% Poorly correlated | -0.97% | ||
SNDL - ANIP | 31% Poorly correlated | -4.27% | ||
PRGO - ANIP | 31% Poorly correlated | -1.43% | ||
More |